Terms: = Bone cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
743 results:
1. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.
Li RQ; Yan L; Zhang L; Ma HX; Wang HW; Bu P; Xi YF; Lian J
Sci Rep; 2024 May; 14(1):12386. PubMed ID: 38811720
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of Prostate cancer Cell Survival and Proliferation by Carnosic Acid Is Associated with Inhibition of akt and Activation of AMPK Signaling.
Nadile M; Sze NSK; Fajardo VA; Tsiani E
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732504
[TBL] [Abstract] [Full Text] [Related]
3. Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.
Gassner T; Chittilappilly C; Pirich T; Neuditschko B; Hackner K; Lind J; Aksoy O; Graichen U; Klee S; Herzog F; Wiesner C; Errhalt P; Pecherstorfer M; Podar K; Vallet S
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702145
[TBL] [Abstract] [Full Text] [Related]
4. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
5. Does Preoperative Radiation Therapy Performed for Metastatic Spine cancer at the Cervical Spine Increase Perioperative Complications of Anterior Cervical Surgery?
Cho JH; Lee DH; Hwang CJ; Park JW; Park JH; Park S
Clin Orthop Surg; 2024 Apr; 16(2):286-293. PubMed ID: 38562630
[TBL] [Abstract] [Full Text] [Related]
6. Microbiome Dysbiosis Is Associated with Castration Resistance and cancer Stemness in Metastatic Prostate cancer.
Uzelac M; Xin R; Ongkeko WM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542265
[TBL] [Abstract] [Full Text] [Related]
7. USP3 promotes osteosarcoma progression via deubiquitinating EPHA2 and activating the PI3K/akt signaling pathway.
Li A; Wang S; Nie J; Xiao S; Xie X; Zhang Y; Tong W; Yao G; Liu N; Dan F; Shu Z; Liu J; Liu Z; Yang F
Cell Death Dis; 2024 Mar; 15(3):235. PubMed ID: 38531846
[TBL] [Abstract] [Full Text] [Related]
8. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
9. Hydroxychloroquine interaction with phosphoinositide 3-kinase modulates prostate cancer growth in bone microenvironment: In vitro and molecular dynamics based approach.
Abdullah KM; Sharma G; Qais FA; Khan I; Takkar S; Kaushal JB; Kanchan RK; Sarwar T; Chakravarti B; Siddiqui JA
Int J Biol Macromol; 2024 May; 266(Pt 1):130912. PubMed ID: 38513896
[TBL] [Abstract] [Full Text] [Related]
10. Screening for Synergistic Reagents With Pazopanib Against Osteosarcoma Using a Compound Library.
Yada Y; Asanuma K; Kakimto T; Okuno K; Okamoto T; Iino T; Nakamura T; Sudo A
Anticancer Res; 2024 Mar; 44(3):1071-1078. PubMed ID: 38423639
[TBL] [Abstract] [Full Text] [Related]
11. Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K/akt pathway.
Wu H; Ma T; He M; Xie W; Wang X; Lu L; Wang H; Cui Y
Phytother Res; 2024 May; 38(5):2215-2233. PubMed ID: 38411031
[TBL] [Abstract] [Full Text] [Related]
12. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
Wang Y; Ma X; Xu E; Huang Z; Yang C; Zhu K; Dong Y; Zhang C
Clin Transl Med; 2024 Feb; 14(2):e1586. PubMed ID: 38372422
[TBL] [Abstract] [Full Text] [Related]
13. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
[TBL] [Abstract] [Full Text] [Related]
14. Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.
Kong Y; Li X; Zhang H; Fu B; Jiang HY; Yang HL; Dai J
Cell Death Dis; 2024 Jan; 15(1):57. PubMed ID: 38228583
[TBL] [Abstract] [Full Text] [Related]
15. Soy isoflavones induces mitophagy to inhibit the progression of osteosarcoma by blocking the akt/mTOR signaling pathway.
Zheng Z; Zhao X; Yuan B; Jiang S; Yan R; Dong X; Yao Q; Liang H
Mol Med; 2024 Jan; 30(1):5. PubMed ID: 38191316
[TBL] [Abstract] [Full Text] [Related]
16. Exploration of anti‑osteosarcoma activity of asiatic acid based on network pharmacology and
Pang H; Wu H; Zhan Z; Wu T; Xiang M; Wang Z; Song L; Wei B
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186298
[TBL] [Abstract] [Full Text] [Related]
17. Solute carrier family 35 member A2 regulates mitophagy through the PI3K/akt/mTOR axis, promoting the proliferation, migration, and invasion of osteosarcoma cells.
Luo X; Zhang J; Guo C; Jiang N; Zhang F; Jiao Q; Xu K; Yang J; Qu G; Lv XB; Zhang Z
Gene; 2024 Mar; 898():148110. PubMed ID: 38151177
[TBL] [Abstract] [Full Text] [Related]
18. Caulis Spatholobi extracts inhibit osteosarcoma growth and metastasis through suppression of CXCR4/PI3K/akt signaling.
Jiang Y; Gao Y; Li X; He F; Liu Y; Wang R
J Orthop Surg Res; 2023 Dec; 18(1):985. PubMed ID: 38129870
[TBL] [Abstract] [Full Text] [Related]
19. bone morphogenetic protein-9 downregulates StAR expression by inducing snail expression via SMAD1/5/8 signaling in human granulosa-lutein cells.
Liu B; Fu B; Zhou S; Wang H; Bi B; Guo M; Cheng JC; Fang L
Mol Cell Endocrinol; 2024 Mar; 582():112126. PubMed ID: 38109991
[TBL] [Abstract] [Full Text] [Related]
20. LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy.
Mai S; Hodges A; Chen HM; Zhang J; Wang YL; Liu Y; Nakatsu F; Wang X; Fang J; Xu Y; Davidov V; Kang K; Pingali SR; Ganguly S; Suzuki M; Konopleva M; Prinzing B; Zu Y; Gottschalk S; Lu Y; Chen SH; Pan PY
Cancer Res; 2023 Dec; 83(24):4047-4062. PubMed ID: 38098451
[TBL] [Abstract] [Full Text] [Related]
[Next]
